Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 18, 2026 06:05 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; Ovid advancing plans to initiate a Phase 2 trial in...
March 18, 2026 06:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Pricing of $60 Million Private Placement

Proceeds expected to support expansion of next-generation GABA-aminotransferase inhibitor, OV329, into tuberous sclerosis complex and infantile spasmsFinancing led by Point72 with participation from...
February 25, 2026 07:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines to treat brain disorders and symptoms caused by...
December 18, 2025 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)

OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator, OV4071There were no treatment-related laboratory findings, no...
December 02, 2025 07:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need,...
November 12, 2025 07:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

Earnings release and leadership
October 03, 2025 07:05 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds

NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant...
October 03, 2025 07:00 ET | Source: Ovid Therapeutics Inc.

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

An expansive biomarker study confirmed OV329 delivered statistically significant inhibition of GABA-AT as measured across multiple metricsOV329 matched or exceeded inhibition demonstrated by...
August 13, 2025 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

Topline results from the OV329 Phase 1 safety, tolerability and biomarker study remain on track for a readout in Q3 2025$7.0 million royalty monetization agreement signed with Immedica Pharma AB for...
July 23, 2025 08:30 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference

Ovid Therapeutics to participate in the BTIG Virtual Biotech Conference